MedPath

Hemorrhoidal Artery Embolization: Longitudinal Impact On Symptoms (HELIOS)

Not Applicable
Active, not recruiting
Conditions
Internal Hemorrhoids
HAE
Registration Number
NCT07179601
Lead Sponsor
University of California, Los Angeles
Brief Summary

Hemorrhoidal artery embolization (HAE) is a novel treatment for symptomatic internal hemorrhoids. HAE involves the deliberate blockage (embolization) of enlarged rectal or hemorrhoidal arteries leading to reduction of abnormal blood flow to the hemorrhoidal tissue. The aim of HAE is to the improve hemorrhoid related symptoms, especially bleeding. Initial reports of HAE have demonstrated that it both safe and effective. Following an initial clinic visit to determine trial candidacy, enrolled patients will be subsequently treated with HAE. Patients will be followed for a year with clinic follow-up visits at 1, 3, 6 and 12 months.

Detailed Description

Hemorrhoidal artery embolization (HAE) is a novel treatment for symptomatic internal hemorrhoids. HAE involves the deliberate blockage (embolization) of enlarged rectal or hemorrhoidal arteries leading to reduction of abnormal blood flow to the hemorrhoidal tissue. The aim of HAE is to the improve hemorrhoid related symptoms, especially bleeding. Initial reports of HAE have demonstrated that it both safe and effective. However, the initial data is limited due to variations in embolization techniques, few studies with prospective long-term follow-up, and studies focusing on patients with only severe symptoms. Further research is needed to understand the specific long-term effectiveness of different embolization materials in a population that more accurately reflects the large number of patients with hemorrhoidal disease who would likely benefit from HAE. The proposed research project includes 22 patients with symptomatic internal hemorrhoids. Following an initial clinic visit to determine trial candidacy, enrolled patients will be subsequently treated with HAE. Patients will be followed for a year with clinic follow-up visits at 1, 3, 6 and 12 months.

Recruitment & Eligibility

Status
ACTIVE_NOT_RECRUITING
Sex
All
Target Recruitment
22
Inclusion Criteria
  • Age 18 to 90 years
  • Ability to give written informed consent and to comply with the follow-up visits
  • Symptomatic hemorrhoidal disease with French Bleeding Score (FBS) of at least four out of nine
  • Refusal of or contraindication to surgery
  • Refusal of or contraindication to other minimally invasive hemorrhoid treatments
  • Grade I to III hemorrhoids
  • Previous anoscopy or colonoscopy demonstrating internal hemorrhoids within 1 year
  • Supply of the CCR from either the SRA or MRA on intra-procedural angiogram prior to embolization
Exclusion Criteria
  • Asymptomatic patients
  • Patients who ever had previous colorectal surgery
  • Grade IV hemorrhoids
  • Colorectal disease other than hemorrhoids that could result in bleeding
  • Anatomic findings on CTA that would preclude successful embolization
  • Contraindication to iodinated contrast
  • Inability to give written informed consent
  • Active infection or malignancy
  • Recent (within 12 months) or active cigarette use
  • History of inflammatory bowel disease
  • Uncorrectable bleeding diathesis
  • Presence of portal hypertension or rectal varices seen on pre-procedure CTA or anoscopy/colonoscopy
  • No SRA or MRA supply to the CCR seen intra-procedural angiogram

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Primary Outcome Measures
NameTimeMethod
Proportion of patients with decrease in bleeding related symptoms of internal hemorrhoids as defined as a two-point decrease in French Bleeding ScoreFrom baseline to 12 months post procedure
Secondary Outcome Measures
NameTimeMethod
Proportion of technically successful HAE proceduresFrom baseline to 12 months post procedure
Change in non-bleeding related symptoms of internal hemorrhoids as measured by the Hemorrhoid Disease Symptom Score (HDSS)From baseline to 12 months post procedure
Change in non-bleeding related symptoms of internal hemorrhoids as measured by the Short Health Scale-Hemorrhoidal Disease (SHSHD)From baseline to 12 months post procedure
Change in pain related to internal hemorrhoids as measured by the Short Health Scale-Hemorrhoidal Disease (SHSHD), Visual Analog Scale (VAS)From baseline to 12 months post procedure
Change in concomitant hemorrhoid medical therapyFrom baseline to 12 months post procedure
Level of patient satisfaction after HAE as determined by four point patient satisfaction questionnaireFrom baseline to 12 months post procedure
Proportion of patients requiring subsequent non-surgical internal hemorrhoid proceduresFrom baseline to 12 months post procedure
Proportion of patients requiring surgical management of their internal hemorrhoidsFrom baseline to 12 months post procedure

Trial Locations

Locations (1)

University of California, Los Angeles

🇺🇸

Los Angeles, California, United States

University of California, Los Angeles
🇺🇸Los Angeles, California, United States

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.